VVUS VIVUS Inc.

VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019

VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019

CAMPBELL, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the Piper Jaffray 31st Annual Healthcare Conference at 1:10 P.M. ET on Tuesday, December 3, 2019 in New York.

An audio webcast of the presentation will be available in the events and presentations section of the Company’s investor relations website, or by .

About VIVUS

VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit .

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “opportunity” and “should,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS’ Form 10-K for the year ended December 31, 2018 as filed on February 26, 2019, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.

Contact:

VIVUS, Inc.Lazar FINN Partners
Mark OkiDavid Carey
Chief Financial OfficerSenior Partner
650-934-5200212-687-1768
EN
25/11/2019

Underlying

VVUSVIVUS Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VIVUS Inc.

 PRESS RELEASE
Free
VVUS VIVUS INC.

VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganizati...

VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganization CAMPBELL, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (the “Company”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on its Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (the “Plan”). The Bankruptcy Court approved the disclosure statement and solicitation procedures and confirmed the second amended chapter ...

December 11, 2020 1 EN
 PRESS RELEASE
Free
VVUS VIVUS INC.

VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter ...

VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date CAMPBELL, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- On November 10, 2020, VIVUS, Inc. (the “Company”), a biopharmaceutical company, filed the Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (as may be amended, modified, or supplemented from time to time, the “Plan”) with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). As set forth in a letter fil...

November 14, 2020 1 EN
 PRESS RELEASE
Free
VVUS VIVUS INC.

VIVUS Completes Solicitation for In-Court Reorganization Plan to Becom...

VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC CAMPBELL, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing.  The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged ...

July 7, 2020 1 EN
 PRESS RELEASE
Free
VVUS VIVUS INC.

VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.

VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P. CAMPBELL, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma LLC), which holds a principal amount of approximately $170.2 million of the Company’s Convertible Senior Notes. Under the terms of the agreement, the Company will continue to work with IEH Biopharma on an exclusive basis in respect of any restructuring, financ...

June 2, 2020 1 EN
 PRESS RELEASE
Free
VVUS VIVUS INC.

VIVUS Reports First Quarter 2020 Financial Results

VIVUS Reports First Quarter 2020 Financial Results Company to host conference call today at 4:30pm ET CAMPBELL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported financial results for the quarter ended March 31, 2020 and provided a business update. “Our ability to respond quickly to the COVID-19 pandemic by successfully accelerating the launch of our telemedicine and remote monitoring modules through the VIVUS Health Platform reflects our commitment to providing patients and physicians with real-world solutio...

May 6, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch